Avidity Biosciences Inc’s filing revealed that its Director LEVIN ARTHUR A unloaded Company’s shares for reported $0.54 million on Apr 03 ’24. In the deal valued at $27.11 per share,20,000 shares were sold. As a result of this transaction, LEVIN ARTHUR A now holds 253,872 shares worth roughly $6.07 million.
Then, Boyce Sarah sold 28,000 shares, generating $734,919 in total proceeds. Upon selling the shares at $26.25, the President and CEO now owns 112,117 shares.
Before that, LEVIN ARTHUR A sold 5,000 shares. Avidity Biosciences Inc shares valued at $119,848 were divested by the Director at a price of $23.97 per share. As a result of the transaction, LEVIN ARTHUR A now holds 14,830 shares, worth roughly $0.35 million.
Cantor Fitzgerald initiated its Avidity Biosciences Inc [RNA] rating to an Overweight in a research note published on March 14, 2024; the price target was $60. A number of analysts have revised their coverage, including Evercore ISI’s analysts, who increased its forecast for the stock in late May from “an In-line” to “an Outperform”. Evercore ISI also remained covering RNA and has decreased its forecast on March 31, 2023 with a “an In-line” recommendation from previously “an Outperform” rating. Chardan Capital Markets started covering the stock on July 20, 2022. It rated RNA as “a Buy”.
Price Performance Review of RNA
On Monday, Avidity Biosciences Inc [NASDAQ:RNA] saw its stock fall -0.75% to $23.91. Over the last five days, the stock has lost -3.51%. Avidity Biosciences Inc shares have risen nearly 164.20% since the year began. Nevertheless, the stocks have risen 56.68% over the past one year. While a 52-week high of $27.66 was reached on 04/03/24, a 52-week low of $4.82 was recorded on 01/02/24. SMA at 50 days reached $19.89, while 200 days put it at $11.10. A total of 0.87 million shares were traded, compared to the trading of 0.8 million shares in the previous session.
Levels Of Support And Resistance For RNA Stock
The 24-hour chart illustrates a support level at 23.54, which if violated will result in even more drops to 23.17. On the upside, there is a resistance level at 24.36. A further resistance level may holdings at 24.81. The Relative Strength Index (RSI) on the 14-day chart is 53.02, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.70, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 61.48%. Stochastics %K at 47.38% indicates the stock is a holding.
The most recent change occurred on July 12, 2022 when Raymond James began covering the stock and recommended ‘”a Strong buy”‘ rating along with a $29 price target.
